NASDAQ OMX

ZAGENO on Growth Trajectory - Startup Becoming #1 Online Marketplace for Life Science Research Products; Raises $8 Million

Dela

BOSTON, Mass., USA, and BERLIN, GERMANY, Oct. 25, 2017 (GLOBE NEWSWIRE) -- ZAGENO Inc., announces successful Series A investment of $8 Million US Dollars led by Capnamic Ventures, with Grazia Equity, lead investor in the seed round, also investing. The investment will be used to fuel growth in the key markets USA and Europe, by ramping up sales, marketing, and technical integration teams.


ZAGENO Launching a New Era of Digital Science and Research

"Just two years old, we are experiencing enormous traction, where global leaders in life science research, such as The Babraham Institute, choose to purchase life science research products through us," said Co-Founder and CEO of ZAGENO David Pumberger. "There is a vast need for digitalization in science and research! We founded ZAGENO with the vision of connecting scientists, administrative departments, and vendors of biotechnology products via one single platform, thereby creating a WIN-WIN-WIN-Situation for everybody involved. Nobody has dared to do that so far," he continued.

What is the WIN-WIN-WIN-situation for scientists, academic research institutes, researching companies, and equipment vendors? For the first time, ZAGENO enables scientists in their laboratories to choose crucial products directly via an online marketplace, from an extensive and high-quality product portfolio. Currently, researchers from 250+ leading research institutions in the U.S. and Europe compare products every day on ZAGENO for their experiments and order directly from across 650+ different vendors. This newly unveiled transparency is an absolute novelty in the biotech industry and saves costs as well as time for researchers.

ZAGENO enables straightforward integration of ordering and purchasing processes into existing software systems. And it is a milestone in the direction of bundled, and therefore, more-efficient, operation flows for academic research institutes and research companies alike. Biotechnology vendors benefit from the ZAGENO online-platform by reaching potential customers right at the buying/decision-making moments. They can also leverage ZAGENO as an additional digital sales channel to increase their reach in the key markets - USA and Europe. Further, the ZAGENO online-platform represents a valuable marketing tool to strengthen brand awareness and foster brand image and thus helps industry players to adapt to existing e-commerce models by increased customer service and content quality.

Commenting on The Babraham Institute's experience with ZAGENO, Michael Norden, the Institute's head of purchasing, said, "ZAGENO enables our 200+ scientists to choose and order life science research products from all vendors using one platform. This further streamlines our purchasing processes and allows us to gain full transparency on our spending. Ultimately, scientists focus on their research while complying with all purchasing requirements. We have found ZAGENO's customer service to be outstanding."

"ZAGENO combines an exceptional team and is the first to unlock an untapped billion dollar U.S. market," said Capnamic Ventures General Partner Christian Siegele.

Founding Partner of Grazia Equity Alec Rauschenbusch commented, "ZAGENO is fantastic. It's a true game-changer, helping the life science industry become more successful."           

ZAGENO's Pumberger added, "Together with our partners and the Series A funding, we will strengthen our position at the interface of technology and biotech, as well as reach our targeted growth in focus markets. We feel very fortunate to grow together with Capnamic Ventures and Grazia Equity and to benefit from their deep industry connections and insights. Consistent with entrepreneurial values, mindsets, and growth targets, we focus on fulfilling customers' needs on all sides of the platform!"

About Capnamic Ventures

Capnamic Ventures (www.capnamic.com) is one of Europe's leading early-stage Venture Capital firms, with offices in Berlin and Cologne. The VC invests most of its funds in tech startups in the German-speaking region. Capnamic also joins forces with international co-investors. All portfolio companies are supported through Capnamic's global network of investors and industry partners.

The vast expertise of the Capnamic team includes more than 70 investments, a high turnover of successful trade sales and IPOs, as well as a strong entrepreneurial track record within the investment team. The general partners are Jörg Binnenbrücker (@bibrue), Olaf Jacobi (@olafjacobi) and Christian Siegele.

For more details, visit capnamic.com or @Capnamic on Twitter.

About Grazia Equity

Grazia Equity, one of Germany's top venture capital firms, has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. Grazia's success derives from a partnership with extraordinarily strong entrepreneurial teams to turn them into international market leaders. In contrast to other venture capital firms Grazia has a solid permanent capital structure ("Evergreen"). Grazia's portfolio companies profit from the entrepreneurial background and the business development expertise of its partner team as well as a far-reaching international network. Being active in Germany, Europe and in the USA Grazia has invested early in category leaders such as Statista, Mister Spex, Conergy, Quantenna, and Yeay.

For more information, please visit grazia.com

About ZAGENO Inc.

Since its formation in 2015, ZAGENO Inc. sets new standards in the international biotech market. With the vision to offer an online marketplace connecting scientists, academic research institutes, and biotech manufacturers, ZAGENO grows exponentially and represents a milestone for the digitization of science and research. World-renowned research facilities use ZAGENO for ordering lab equipment and for optimizing internal processes. The start-up employs 35 staff members in Boston (USA) and Berlin (Germany). These two locations were selected to be close to centers known for research advancements and scientific breakthroughs. For more "EUREKA"-moments - welcome to ZAGENO: https://zageno.com/

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8f25a44f-43ac-4555-89c9-88e214485457

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4121b588-dce2-4b4c-81f5-1375ea13b05b

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b62c1ccf-4885-4563-813c-5f4596194fd2

Media Contact: Caroline Grossman
(781) 771-5579
Caroline@Mirepoixllc.com

Company Contact: Florian Wegener, MD, PhD, MBA, Chief Revenue Officer
ZAGENO Inc.
pr@zageno.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ZAGENO, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Standard Lithium Announces Closing of $21.6 million Bought Deal Private Placement of Units16.2.2018 19:25Pressmeddelande

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) announced today that it has closed its previously announced bought deal private placement of 10,312,821 units of the Company (the "Units"), at a price of $2.10 per Unit, for aggregate gross proceeds to the Company of $21,656,924, including the issuance and sale of the Underwriters' (as defined below) option (the "Offering"). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant is exercisable to acquire one common share of the Company (a "Warrant Share") until February 16, 2020 at an exercise price of $2.60 per Warrant Share, subject to adjus

Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers16.2.2018 14:00Pressmeddelande

Cisco's comprehensive cloud-based security endpoint portfolio provides advanced malware protection, internet security, and enterprise mobility management SAN JOSE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Cisco today is helping address the challenges of Managed Security Service Providers (MSSP) and their customers by offering MSSPs comprehensive security, visibility, and control of customer endpoints without added hardware or complexity. The Cisco endpoint security portfolio includes three industry-leading solutions-Cisco AMP for Endpoints, Cisco Umbrella, and Meraki Systems Manager to offer protection against advanced malware and threats. Security teams know the endpoints in their environments are being targeted by advanced threats, but often lack the security talent, tools, and budget to address those challenges. As a result, organizations of all sizes are choosing to augment their in-house IT security with managed security services. Nearly half of SMBs and enterprises in the US1 ar

Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family16.2.2018 14:00Pressmeddelande

Aurora Solar Technologies Inc. / Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. NORTH VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora") ("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82) is pleased to provide an update on the further development of its Decima Gemini(TM) infrared measurement technology for applications in the rapidly developing heterojunction (HJT) cell manufacturing market. HJT is an ultra high-efficiency solar cell design pioneered by Japan's Panasonic Corp., who is now also partnered with Tesla Inc. for solar products. According to Solar Media Ltd., HJT production capacity is expected to increase by 20 percent this year. To produce the electrical structure of a HJT cell, it is necessary to apply thin layers of amorphous silicon on both sides of a crystallin

Nasdaq Cited as a Leader in Governance, Risk, and Compliance Platforms by Independent Research Firm16.2.2018 13:35Pressmeddelande

NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) was among the select companies that Forrester invited to participate in its 2018 Forrester Wave(TM) evaluation, Governance, Risk, And Compliance (GRC) Platforms, Q1 2018. In this evaluation, Nasdaq was cited as a Leader in Governance, Risk, and Compliance Platforms and received the maximum score of 5 for the evaluation criteria "Risk & Control Management", "Audit Management", "Dashboard and Reporting" and "Integration capabilities" for its BWise solutions. "We feel the strong scores we obtained in important functional areas provide assurance to our clients that they have selected a robust and future-proof software platform," said Tom Passon, Head of Product Innovation & Global Standards, Nasdaq BWise. "We are proud of this recognition that encourages us to further execute on our strategy to provide user-friendly, pre-configured best practice solutions that combine our innovative GRC software platform with leading expertis

Mandalay Resources Provides Target Release Date for Fourth Quarter and Full-Year 2017 Financial Results and Conference Call16.2.2018 13:30Pressmeddelande

TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or "the Company") (TSX:MND) today announced that its fourth quarter and full-year 2017 financial results will be released after market close on February 21, 2018, followed by a conference call with Mark Sander, President and Chief Executive Officer of Mandalay, for investors and analysts on February 22, 2018 at 8:00 am (Toronto time). Analysts and interested investors are invited to participate using the following dial-in numbers: Participant Number: (201) 689-8341 Participant Number (Toll free): (877) 407-8289 Conference ID: 13676606 A replay of the conference call will be available until 11:59 pm (Toronto time), March 8, 2018 and can be accessed using the following dial-in number: Encore Toll Free Dial-in Number: (877) 660-6853 Encore ID: 13676606 For Further Information: Mark Sander President and Chief Executive Officer Greg DiTomaso Director of Investor Relations Contact: +1.647.260.1566 About Man

Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)16.2.2018 13:00Pressmeddelande

Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration ("FDA") has issued a complete response letter ("CRL") for the New Drug Application ("NDA") of Vitaros(TM) (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction. The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control ("CMC") and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation. "We are disappointed with the outcome of the review given the substantial amount of CMC, clinical and non-clinical data and analysis provided to the FDA in the Vitaros resubmission. We are assessing the content of the complete response

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum